Manufacturing Collaboration Antharis recently announced an exclusive licensing agreement with Lonza to develop dual-payload ADCs for gastrointestinal cancers, signaling a need for advanced CMC and scalable manufacturing capabilities. This creates a sales opening for end-to-end ADC development, GMP manufacturing, analytical development, and supply-chain services to support clinical and potential commercial production.

Clinical Development With plans to initiate multiple clinical trials in 2025 across its asset pipeline, Antharis will require partner support in clinical operations, regulatory affairs, trial management, biomarker strategy, and data generation across regions. Potential sales opportunities include CRO services, biomarker assay development, imaging and translational science collaborations, and regulatory consulting.

Platform Partnerships Antharis emphasizes next-generation mAbs, bispecifics, and ADCs built on proprietary engineering and target biology, suggesting openness to licensing or co-developing platform components such as payloads, linkers, or antibody formats. This presents opportunities to propose technology licensing, collaboration deals, or research services to expand their platform capabilities.

Growth via M&A The strategic acquisitions of Cassyni Biopharma and Galileo Biotech indicate an active pipeline expansion through external assets, which typically requires integration support, due diligence, and partner networks across development, manufacturing, and commercialization. Opportunities exist to partner on asset integration, external vendor alignment, and regional manufacturing or distribution arrangements.

Global Reach Positioned as a multinational biotech with activity across Basel, San Diego and beyond, Antharis will likely need global regulatory, market access, and regional clinical trial support as it advances toward trials and potential commercialization. Sales angles include regulatory affairs outsourcing, clinical trial site networks, and regional manufacturing or logistics partnerships.